Seagen Reports Q3 Miss, Revenues Beat, 2022 Guidance Raised
Seagen (NASDAQ:SGEN) reported its Q3 results, with EPS of ($1.03) coming in worse than the Street estimate of ($0.95). Revenue was $510 million, compared to the Street estimate of $459.58 million.
The company raised its fiscal 2022 net product sales guidance (including Adcetris, Tukysa, and Padcev) to $1.580–1.615 billion from $1.500–1.565 billion driven by strong Adcetris momentum and less-than-expected impact on Tukysa in 2022.
The company also confirmed the submission of an sBLA to FDA in October for Padcev+Keytruda in 1L la/mUC. CEO search efforts continue and the timing of several catalysts from the pipeline has been updated.
| Symbol | Price | %chg |
|---|---|---|
| 207940.KS | 939000 | 0 |
| 068270.KS | 192500 | 0 |
| 196170.KQ | 277000 | 0 |
| 091990.KQ | 75900 | 0 |
SGEN Ratings Summary
SGEN Quant Ranking
Related Analysis
